TY - JOUR AU - Singer, M. AU - Deutschman, C. S. AU - Seymour, C. W. AU - Shankar-Hari, M. AU - Annane, D. AU - Bauer, M. PY - 2016 DA - 2016// TI - The third international consensus definitions for sepsis and septic shock (Sepsis-3) JO - JAMA. VL - 315 UR - https://doi.org/10.1001/jama.2016.0287 DO - 10.1001/jama.2016.0287 ID - Singer2016 ER - TY - JOUR AU - Britt, N. S. AU - Ritchie, D. J. AU - Kollef, M. H. AU - Burnham, C. A. AU - Durkin, M. J. AU - Hampton, N. B. PY - 2018 DA - 2018// TI - Importance of site of infection and antibiotic selection in the treatment of carbapenem-resistant Pseudomonas aeruginosa sepsis JO - Antimicrob Agents Chemother VL - 62 UR - https://doi.org/10.1128/AAC.02400-17 DO - 10.1128/AAC.02400-17 ID - Britt2018 ER - TY - STD TI - Aggarwal R, Dewan A. Comparison of nephrotoxicity of colistin with polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018;17:15. https://doi.org/10.1186/s12941-018-0262-0. ID - ref3 ER - TY - JOUR AU - Zhanel, G. G. AU - Wiebe, R. AU - Dilay, L. AU - Thomson, K. AU - Rubinstein, E. AU - Hoban, D. J. PY - 2007 DA - 2007// JO - Drugs. VL - 67 UR - https://doi.org/10.2165/00003495-200767070-00006 DO - 10.2165/00003495-200767070-00006 ID - Zhanel2007 ER - TY - JOUR AU - Taccone, F. S. AU - Cotton, F. AU - Roisin, S. AU - Vincent, J. L. AU - Jacobs, F. PY - 2012 DA - 2012// TI - Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock JO - Antimicrob Agents Chemother VL - 56 UR - https://doi.org/10.1128/AAC.06389-11 DO - 10.1128/AAC.06389-11 ID - Taccone2012 ER - TY - JOUR AU - Saçar, S. AU - Turgut, H. AU - Cenger, D. H. AU - Coşkun, E. AU - Asan, A. AU - Kaleli, I. PY - 2007 DA - 2007// TI - Successful treatment of multidrug resistant Acinetobacter baumannii meningitis JO - J Infect Dev Ctries VL - 1 UR - https://doi.org/10.3855/jidc.376 DO - 10.3855/jidc.376 ID - Saçar2007 ER - TY - JOUR AU - Sinnollareddy, M. J. AU - Roberts, M. S. AU - Lipman, J. AU - Roberts, J. A. PY - 2012 DA - 2012// TI - Beta-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review JO - Clin Exp Pharmacol Physiol VL - 39 UR - https://doi.org/10.1111/j.1440-1681.2012.05715.x DO - 10.1111/j.1440-1681.2012.05715.x ID - Sinnollareddy2012 ER - TY - JOUR AU - Hidaka, S. AU - Goto, K. AU - Hagiwara, S. AU - Iwasaka, H. AU - Noguchi, T. PY - 2010 DA - 2010// TI - Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF) JO - Yakugaku Zasshi VL - 130 UR - https://doi.org/10.1248/yakushi.130.87 DO - 10.1248/yakushi.130.87 ID - Hidaka2010 ER - TY - JOUR AU - Cirillo, I. AU - Vaccaro, N. AU - Balis, D. AU - Redman, R. AU - Matzke, G. R. PY - 2011 DA - 2011// TI - Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem JO - Antimicrob Agents Chemother VL - 55 UR - https://doi.org/10.1128/AAC.01063-10 DO - 10.1128/AAC.01063-10 ID - Cirillo2011 ER - TY - JOUR AU - Ohchi, Y. AU - Hidaka, S. AU - Goto, K. AU - Shitomi, R. AU - Nishida, T. AU - Abe, T. PY - 2011 DA - 2011// TI - Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration JO - Yakugaku Zasshi VL - 131 UR - https://doi.org/10.1248/yakushi.131.1395 DO - 10.1248/yakushi.131.1395 ID - Ohchi2011 ER - TY - JOUR AU - Roberts, J. A. AU - Udy, A. A. AU - Bulitta, J. B. AU - Stuart, J. AU - Jarrett, P. AU - Starr, T. PY - 2014 DA - 2014// TI - Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous hemodiafiltration JO - J Antimicrob Chemother VL - 69 UR - https://doi.org/10.1093/jac/dku177 DO - 10.1093/jac/dku177 ID - Roberts2014 ER - TY - JOUR AU - Vossen, M. G. AU - Wenisch, J. M. AU - Maier-Salamon, A. AU - Fritsch, A. AU - Saria, K. AU - Zuba, C. PY - 2015 DA - 2015// TI - Doripenem treatment during continuous renal replacement therapy JO - Antimicrob Agents Chemother VL - 60 UR - https://doi.org/10.1128/AAC.01801-15 DO - 10.1128/AAC.01801-15 ID - Vossen2015 ER - TY - JOUR AU - Yamamoto, T. AU - Yasuno, N. AU - Katada, S. AU - Hisaka, A. AU - Hanafusa, N. AU - Noiri, E. PY - 2011 DA - 2011// TI - Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration JO - Antimicrob Agents Chemother VL - 55 UR - https://doi.org/10.1128/AAC.01758-10 DO - 10.1128/AAC.01758-10 ID - Yamamoto2011 ER - TY - JOUR AU - Ikeda, K. AU - Ikawa, K. AU - Morikawa, N. AU - Kameda, K. AU - Urakawa, N. AU - Ohge, H. PY - 2008 DA - 2008// TI - Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection JO - J Chromatogr B Analyt Technol Biomed Life Sci VL - 867 UR - https://doi.org/10.1016/j.jchromb.2008.03.001 DO - 10.1016/j.jchromb.2008.03.001 ID - Ikeda2008 ER - TY - JOUR AU - Kuti, J. L. AU - Dandekar, P. K. AU - Nightingale, C. H. AU - Nicolau, D. P. PY - 2003 DA - 2003// TI - Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem JO - J Clin Pharmacol VL - 43 UR - https://doi.org/10.1177/0091270003257225 DO - 10.1177/0091270003257225 ID - Kuti2003 ER - TY - JOUR AU - Yadav, R. AU - Bulitta, J. B. AU - Nation, R. L. AU - Landersdorfer, C. B. PY - 2016 DA - 2016// TI - Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic/pharmacodynamic modeling JO - Antimicrob Agents Chemother VL - 61 UR - https://doi.org/10.1128/AAC.01011-16 DO - 10.1128/AAC.01011-16 ID - Yadav2016 ER -